Studies show mixed results from combination therapies with osimertinib plus bevacizumab, and monotherapies with tarloxotinib or patritumab deruxtecan

Breaking data from the IMpassion031 trial provides further evidence to support a role for immunotherapy in early-stage triple negative breast cancer (TNBC).

In a Chinese study, HAIC using FOLFOX significantly improved overall survival compared with TACE, but is more complex to deliver to patients

[5:08 PM] Cinzia POZZI - ESMOchange the subtitle into: In a Chinese study, HAIC using FOLFOX significantly improved overall survival compared with TACE, but is more complex to deliver to patients

The ALK tyrosine kinase inhibitor lorlatinib significantly improved progression-free survival compared with crizotinib

In the Phase III trial, sacituzumab govitecan significantly improved progression-free survival and overall survival over standard chemotherapy

Mixed results from IMpassion 130 and IMpassion 131 also draw attention to chemotherapy backbone selection 

Results support the use of alpelisib plus fulvestrant for patients with HR-positive, HER2-negative advanced breast cancer and PI3KCA mutations

Dr Susana Banerjee summarises results from two surveys investigating the psychological impact of the pandemic on medical oncologists

Results from the PRODIGE 13 trial, presented at ESMO Virtual Congress 2020, show that optimisation of diagnostic procedures in terms of overall survival benefits remains to be determined

Although disappointing, results from IONESCO and PRINCEPS trials are preliminary